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Rationale and design of the Hunting for the
off-target propertIes of Ticagrelor on
Endothelial function and other Circulating
biomarkers in Humans (HI-TECH) trial
Sara Ariotti, MD, a Maarten van Leeuwen, MD, PhD, b Salvatore Brugaletta, MD, PhD, c Sergio Leonardi, MD, PhD, d
Kristiaan Martijn Akkerhuis, MD, PhD, e Emrush Rexhaj, MD, PhD, a Gladys Janssens, MD, b Luis Ortega-Paz, MD, c
DiegoRizzotti,MSc, d JanC. van denBerge,MD, e DierikHeg, PhD, f Gloria Francolini, CLS, g StephanWindecker,MD, a
and Marco Valgimigli, MD, PhDa, The HI-TECH Investigators Bern, Switzerland; Amsterdam, Rotterdam, the
Netherlands; Barcelona, Spain; Pavia, and Brescia, ItalyBackground Among the 3 approved oral P2Y12 inhibitors for the treatment for patients with acute coronary syndrome
(ACS), ticagrelor, but not prasugrel or clopidogrel, has been associated with off-target properties, such as improved 
endothelial-dependent vasomotion and increased adenosine plasma levels.
Methods The HI-TECH study (NCT02587260) is a multinational, randomized, open-label, crossover study with a Latin 
squares design, conducted at 5 European sites, in which patients free from recurrent ischemic or bleeding events ≥30 days after a 
qualifying ACS were allocated to sequentially receive a 30 ± 5-day treatment with prasugrel, clopidogrel, and ticagrelor in random 
order. The primary objective was to evaluate whether ticagrelor, at treatment steady state (ie, after 30 ± 5 days of drug administration), 
as compared with both clopidogrel and prasugrel, is associated with an improved endothelial function, assessed with peripheral 
arterial tonometry. Thirty-six patients undergoing evaluable endothelial function assessment for each of the assigned P2Y12 inhibitor 
were needed to provide 90% power to detect a 10% relative change of the reactive hyperemia index in the ticagrelor group.
Conclusion The HI-TECH study is the first randomized, crossover study aiming to ascertain whether ticagrelor, when 
administered at approved regimen in post-ACS patients, improves endothelial function as compared with both clopidogrel and 
prasugrel.Background
Oral P2Y12 inhibitors are key secondary prevention
medications after coronary stent implantation or acute
coronary syndromes (ACSs). Ticagrelor, unlike other oral
P2Y12 inhibitors, has been associated with off-target
effects, such as an improvement in endothelial function
assessed by peripheral arterial tonometry, as recently
reported in a nonrandomized trial.1 Moreover, in a recentFrom the aBern University Hospital, Bern, Switzerland, bVU University Medical Center, 
Amsterdam, the Netherlands, cCardiovascular Clinic Institute, Hospital Clinic, University of 
Barcelona, IDIBAPS, Barcelona, Spain, dFondazione IRCCS Policlinico S. Matteo, Pavia, 
Italy, eErasmus University Medical Center, Rotterdam, the Netherlands, fClinical Trials Unit 
and Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland, and 
gIstituti Clinici Scientifici Maugeri—IRCCS Lumezzane, Brescia, Italy.
NCT02587260
Submitted December 4, 2016; accepted March 25, 2017.
Reprint requests: Marco Valgimigli, MD, PhD, Department of Cardiology, Bern University 
Hospital, SH1 307, Freiburgstrasse 4, 3010 Bern, Switzerland.
E-mail: marco.valgimigli@insel.chrandomized trial of 60 ACS patients, 30-day ticagrelor
administration was shown to increase reactive hyperemia
index (RHI) by 100% as compared with baseline
measurement, and this improvement was correlated
with adenosine plasma levels (APLs).2 A recent observa-
tional study also reported no change in endothelial
function at 2 and 5 days after treatment discontinuation
with ticagrelor, which was interpreted as evidence that
the treatment effect on endothelial function does not
immediately cease after treatment cessation.3
Endothelial dysfunction is a systemic condition mainly
characterized by an imbalance between endothelium-
derived relaxing factors (ie, nitric oxide [NO])4 and
endothelium-derived contracting factors (ie, endothelin),5
clinically correlated with most cardiovascular risk factors.6
Endothelial dysfunction appears to precede the clinical
manifestation of atherosclerotic disorders and predicts
clinical outcome.7 Thus, it can be considered a barometer
of the total risk burden.8-10
The “ticagrelor-related pleiotropic effects” are possibly
mediated by the inhibition of adenosine uptake into
Table. Inclusion and exclusion criteria
Inclusion criteria
1. Age N18 y
2. ACS (including STEMI or NSTEMI) at least 30 d before randomization
3. Ongoing treatment with DAPT since at least 30 d, consisting of ASA 75-160 mg daily and 1 of the 3 available P2Y12
inhibitors (ticagrelor, prasugrel, or clopidogrel)
4. No bleeding events (defined as BARC type 2 or greater) or ischemic recurrences in the period between the ACS and the
study randomization
Exclusion criteria
1. Administration of fibrinolytics or glycoprotein IIb/IIIa inhibitors in the previous 30 d
2. Major surgery within 30 d or any planned surgical or percutaneous intervention
3. Active bleeding or previous clinically relevant bleeding in the last 6 mo
4. Previous TIA or stroke in the last 6 mo
5. Previous intracranial bleeding
6. Thrombocytopenia
7. Ongoing anticoagulant therapy or clinical indication to start with anticoagulant agents
8. Vasculitis or any known immunological disorder
9. Severe hepatic failure
10. Uncontrolled hypertension (systolic or diastolic arterial pressure N 180 mmHg or 120 mmHg, respectively, despite
medical therapy)
11. Known intolerance to aspirin, clopidogrel, prasugrel, or ticagrelor
12. Limited life expectancy (ie, neoplasms)
13. Inability to obtain the informed consent
14. Pregnancy
Abbreviations: STEMI, ST-segment elevation myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; ASA, aspirin; BARC, Bleeding Academic Research
Consortium; TIA, transient ischemic attack.
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reported.2,11,12
Adenosine is released in the plasma by endothelial cells
and myocytes during ischemia, hypoxia, or oxidative
stress, and quickly taken up by red blood cells through a
facilitated diffusion transport system (sodium-indepen-
dent equilibrative nucleoside transporters 1 and 2;
sodium-dependent concentrative nucleoside transporters
1 and 2) or converted into inosine by adenosine
deaminase activity. Ticagrelor increases APL mainly
through inhibition of equilibrative nucleoside transporter
1. 11 After binding to 4 different purinergic receptors (A1,
A2A, A2B, A3), an increase in APL may determine (1)
vasodilation, (2) reduction in ischemia/reperfusion injury
and electrical conduction, (3) increase of platelet
inhibition, (4) decrease of glomerular filtration rate, and
(5) rise of dyspnea incidence. Finally, ticagrelor induces
adenosine triphosphate release from human red blood
cells in a dose-dependent manner,13 which may contrib-
ute to increasing APL. It remains, however, unclear
whether the off-target properties of ticagrelor, which
were discovered and characterized in animals or ex vivo
models,14,15 contribute to its clinical effects in humans at
currently approved regimen.Methods
Study design and population
The HI-TECH study (ClinicalTrial.gov NCT02587260) is
a multinational, randomized, open-label, crossover study
with a Latin squares design conducted at 5 European sites
and including 54 patients, aiming to assess whether
ticagrelor, as compared with both clopidogrel and
prasugrel, improves endothelial function. Eligible pa-
tients were older than 18 years treated for an ACS,
including ST-segment elevation myocardial infarction,
non–ST-segment elevation myocardial infarction, or
unstable angina, at least 30 days before randomization,
and receiving dual antiplatelet therapy (DAPT) since at
least 30 days before randomization. Patients were free
from bleeding events (defined as Bleeding Academic
Research Consortium classification16 type 2 or greater) or
ischemic recurrences (unstable angina or myocardial
infarction, which required a repeated revascularization)
since the index event. Patients with transient ischemic
attack or stroke in the previous 6 months, those who
received fibrinolytic therapy or glycoprotein IIb/IIIa
inhibitors in the previous 30 days; those with indication
for oral anticoagulant therapy, or with vasculitis, immu-
nological disorders, thrombocytopenia, severe hepatic
Figure 1
Study design. Study flowchart depicting study visits with the respective time intervals (black arrows on top) and all procedures performed at each
time point. Endothelial function evaluation is performed using EndoPAT in all sites, whereas FMD was performed only for patients recruited in Bern.
Blood was collected for dosage of circulating biomarkers. VerifyNow measurements, using both P2Y12 and ASA assays, were obtained to assess
platelet reactivity. V1 indicates visit 1; V2, visit 2; V3, visit 3; V4, visit 4; V5, visit 5; V6, visit 6; MD, maintenance dose; T1, 1-2 hours after
ticagrelor LD administration; T2, before ticagrelor MD administration; T3, 1-2 hours after ticagrelor MD administration; P1, 1-2 hours after
prasugrel LD administration; P2, before prasugrel MD administration; P3, 1-2 hours after prasugrel MD administration; C1, 1-2 hours after
clopidogrel LD administration; C2, before clopidogrel MD administration; C3, 1-2 hours after clopidogrel MD administration; S, sequence;
P, prasugrel; T, ticagrelor; C, clopidogrel.
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pressure N 180 or 120 mmHg, respectively, despite
medical therapy), or known intolerance to aspirin,
clopidogrel, prasugrel, or ticagrelor; and those with
limited life expectancy (eg, neoplasm) as well as patients
who underwent major surgery within 30 days before
randomization orwith any planned surgical or percutaneous
intervention were excluded (Table).
A Latin square design was used to have a uniform
crossover design in that each treatment occurred only
once within each sequence and once within each period.
Moreover, each treatment preceded every other
treatment the same number of times (twice), and
consequently, our design was balanced with respect to
first-order carryover effects (balanced Latin square
design). The crossover study design was chosen so tohave an “in-within” control of the effect of each P2Y12
inhibitor on endothelial function (in the same patient) as
opposed to an “in-between” control (different patients).
Supplementary Table I displays the 6 randomized
treatment sequences. Adherence to study treatment was
assessed by electronic Medication Event Monitoring
System, pill count, and patient interview (see Supple-
mentary Appendix).
Follow-up visits
The study included 6 follow-up visits, counting a total of
10 study intervals: baseline (B), 1-2 hours after loading
dose (LD) intake of each P2Y12 inhibitor (C1, P1, T1), and
before (C2, P2, T2) and 1-2 hours after MD intake of each
P2Y12 inhibitor (C3, P3, T3) (Figure 1). The LD of the first
randomized P2Y12 inhibitor was administered at visit 1,
Figure 2
EndoPAT measurement. A, RHI measurement after EndoPAT assessment. A = mean PAT amplitude between 90 and 150 s after occlusion of the test
arm; B = mean PAT amplitude from the baseline period on the test arm; C = mean PAT amplitude between 90 and 150 s after occlusion of the
control arm; D = mean PAT amplitude from the baseline period of the control arm. B, LnRHI measurement after EndoPAT assessment. A = mean
PAT amplitude between 90 and 120 s after occlusion of the test arm; B = mean PAT amplitude from the baseline period on the test arm; C = mean
PAT amplitude between 90 and 120 s after occlusion of the control arm; D = mean PAT amplitude from the baseline period of the control arm.
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ments 1-2 hours thereafter (Figure 1). Pre- and post-MD
evaluations of the ongoing P2Y12 inhibitor were per-
formed after 30 ± 5 days of treatment at visit 2 (V2). The
administration of the second randomized P2Y12 inhibitor
at visit 3 occurred 1 to 7 days after visit 2, and the related
measurements were collected 1-2 hours after LD admin-
istration (Figure 1). An identical scheme was then
followed for the second and third randomized P2Y12
inhibitor (Figure 1). No washout time was allowed among
the 3 oral P2Y12 inhibitors because of ethics consider-
ations. At each follow-up, patients were requested to fast
for at least 2 hours before the visit; caffeine-containing
beverages were not permitted at any time the day of the
visit. Patients were reminded 1-2 days before each study
visit about these dietary restrictions.
Finger plethysmography
Pulse amplitude tonometry (PAT) is an operator-independent,
Food and Drug Administration–approved method to
measure the endothelium-dependent dilation in response
to reactive hyperemia.10 The PAT device records digital
pulse wave amplitude using fingertip plethysmography
(EndoPAT; Itamar Medical Ltd, Caesarea, Israel) and
quantifies the endothelium-mediated changes in vascular
tone, elicitedby a 5-minute occlusionof thebrachial artery. A
postocclusion-to-preocclusion ratio (Figure 2) is calculatedby the EndoPAT software and expressed as RHI (Figure 2A)
or its natural logarithm variant (LnRHI; Figure 2B). These
values are normalized to measurements from the contralat-
eral arm, which serves as control for nonendothelial
dependent systemic effects. An RHI value less than 1.67 or
an LnRHI value less than 0.51 denotes an endothelial
dysfunction.8 EndoPAT was found to be well correlated
with coronary endothelial function, evaluated by quantita-
tive coronary angiography after injection of acetylcholine,8
as well as with the conventional cardiovascular risk
factors.17,18 EndoPAT measurement was able to identify
patients with early coronary atherosclerosis8 and predicts
late cardiovascular adverse events.10 EndoPAT reliabilitywas
tested in healthy adults and adolescents, and it was shown to
behighly reproducible across intervals of 1 day19 and1week
or longer.20-22 Description of technical procedure is
reported in Supplementary Appendix.
Methodological advantages of this technology are as
follows: (1) simultaneous recording from both arms with
an intrasubject control, (2) live assessment of occlusion
and provocation quality to avoid incomplete occlusion
during the examination, (3) large dynamic range of
measurements due to the finger ability to vary local
vascular tone, and (4) operator independency as all
analyses are automated. Limitations to this assessment
include the following: (1) the assessment of endothelial
function at a microcirculation level instead of at medium
Figure 3
Assessment of FMD and EndoPAT at Bern University Hospital. The picture shows the concomitant acquisition of FMD and EndoPAT measurements
at Bern University Hospital.
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via standard flow-mediated dilatation; (2) the use of a
fixed time frame during the hyperemic response to
calculate the EndoScore, whereas the maximal hyper-
emic response can occur with different delays for each
patient, especially in older subjects23; (3) the influence of
autonomous nervous system or the temperature study
room on finger vascular tone; and (4) limited knowledge
about the effect of circadian variation on RHI result.
Flow-mediated dilation
Flow-mediated dilation (FMD) of brachial artery is a
noninvasive technique widely used to assess endothelial
function. The FMD result is reported as a percentage
change between the peak diameter in response to
reactive hyperemia, after 5 minutes of artery occlusion,
and the baseline diameter using the following equation:
FMD %ð Þ ¼
Peak diameter−Baseline diameterð Þ=Baseline diameter 100:
Moreover, the FMDevaluation after nitrate administration is
able to differentiate the endothelium-independent vasodila-
tion component due to alterations in smooth and not
endothelial cell function, improving the endothelial function
assessment. However, although the principle seems simpleand many laboratories showed robust test-retest reliability for
FMD under standardized conditions,24-26 appropriate
high-resolution ultrasound equipment and highly skilled
personnel are essential for obtaining an accurate and reliable
measurement.18,20,27 Ghiadoni et al27 evaluated the FMD
twice in the same day and subsequently after 30 days after a
dedicated training program in the setting of a multicenter
evaluation of 135 healthy volunteers. Values of FMD did not
differ over time and showed an intrasession coefficient of
variation ranging from 7.6% to 11.9% and an intersession
coefficient of variation ranging from 11.6% to 16.1% across
centers. No data have been, however, provided in patients
with coronary artery disease who may have higher intrases-
sion and intersession variability. Furthermore, it remains
challenging to standardize FMD protocol and technical
expertise across different sites. Therefore, we evaluated the
endothelial function using the FMD jointly to the EndoPAT
technology (Figure 3), only in one study center—Bern
University Hospital, Switzerland, with large prior experience
with this methodology.28-31 Description of technical proce-
dure is reported in Supplementary Appendix.
Circulating biomarkers
Plasma levels of various circulating biomarkers have
been associated with the presence of endothelial
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in final edited form as: Am Heart J. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.017dysfunction. Endothelin-1 is a 21-amino-acid peptide
synthesized from a larger preproET-1 precursor that
elicits its vasoconstrictor properties binding 2 G-protein–
coupled receptors, ETA and ETB, located on vascular
smooth muscle cells, fibroblasts, and endothelial cells
(ETB only). Endothelin-1 induces endothelial dysfunction
reducing NO bioavailability through 2 different ways: (1)
decreasing its production via caveolin-1–mediated inhibition of
eNOS activity and (2) increasing its degradation via formation of
oxygen radicals.32 Accordingly, high levels of ET-1 may
represent an indirect index of endothelial dysfunction.
Asymmetric dimethylarginine (ADMA) is an analogue of
L-arginine found in human circulation and represents
a naturally occurring endogenous inhibitor of NO
synthase.33 Reducing NO production, ADMA could
thus lead to endothelial dysfunction and cardiovascular
events. Elevated plasma ADMA concentration has been
identified as an independent risk factor for progression of
atherosclerosis, cardiovascular death, and all-cause
mortality.34-36
von Willebrand factor (vWF) is a multimeric glycopro-
tein synthesized exclusively in endothelial cells and 
megakaryocytes and released when endothelial cells are 
damaged. Thus, high level of circulating vWF may reflect 
endothelium damage or endothelial dysfunction. The 
close association between vWF and thrombogenensis or 
atherogenesis also suggests that high vWF levels may be a 
useful indirect indicator of atherosclerosis and/or thrombosis.37
Blood collection was to be performed after EndoPAT 
assessment at each time point, using the control arm as 
sampling site for the quantification of ADMA, vWF 
antigen, and ET-1. To assess the relationship between 
residual platelet reactivity or percentage inhibition and 
effect of P2Y12 oral blocker on endothelial function, a 
platelet function testing was also to be carried out using the 
VerifyNow (Accumetrics - Accriva diagnostics - United 
States) system using both P2Y12 and aspirin assays.
Markers of thrombin activity such as prothrombin fragment  
1 + 2, fibrinopeptide A, and thrombin-antithrombin complex 
(TAT) were also measured for exploratory purpose. All 
circulating biomarkers reported above were predefined and 
will be analyzed by a centralized laboratory (Istituti Clinici 
Scientifici Maugeri, IRCCS Lumezzane, Brescia, Italy). 
C-reactive protein will be measured with an immunoturbi-
dimetric assay, whereas all the other biomarkers will be 
measured using commercially available enzyme-linked 
immunosorbent assay tests (Supplementary Table II), 
including the vWF antigen, for which the enzyme-linked 
immunosorbent assay test is a well-validated method of 
measurement.38-40 Finally, to provide mechanistic data on 
how ticagrelor may be associated with improved endothe-
lial function, adenosine plasma concentration, ticagrelor 
and its metabolite AR-C124910XX will be dosed in 2 
different reference laboratories (Q&Q Labs AB, Bio 
VentureHub, Mölndal, Sweden, and Bioanalytical Covance 
Laboratory, Indianapolis, IN, respectively). An overview of 
all investigated biomarkers with the correspondingcollection time points is shown in Supplementary Table I.
Protocols of sample collection, centrifugation, and storage
were standardized in all sites (preanalytical standardization)
and are reported in Supplementary Table IV. When
immediately frozen at −20°C (as stored in Amsterdam,
Barcelona, Pavia, and Bern), or −80°C (as stored in
Rotterdam), after centrifugation and never thawed, all
assessed biomarkers are known to be stable in vitro for a
long time (at least few years). The only exception is
represented by adenosine, which is immediately degraded
after blood collection with a half-life of a few seconds. To
improve adenosine stability and allow its subsequent dosage,
a stopping solution was immediately added to blood tube
during sampling.
Collection of adenosine samples
Adenosine plasma samples were collected as described
by Bonello et al.12 Venous blood (2.6 mL) was withdrawn
under vacuum together with a STOP solution previously
placed in S-Monovette 2.6 mL, K3 EDTA (Sarstedt,
Nümbrecht, Germany). This method allows blood sample
to be mixed rapidly with 4 mL of STOP solution, which
prevents adenosine degradation and uptake. The STOP
solution was composed of NBMPR 0.1 mml/L, dipyridamole
0.04 mmol/L, AMPCP 0.22 mmol/L, ethylene-diamine-
tetraacetic acid disodium salt dehydrate 15 mmol/L,
5-iodotubericidin 0.1 mmol/L, and erythro-9-(2-
hydroxy-3-nonyl)-adenine 0.1 mmol/L dissolved in phosphate-
buffered saline, pH7.4, 0.01mmol/L (Supplementary Table
V). The sample with the STOP solution was centrifuged
at 1640g for 10minutes at room temperature. The plasma
supernatant was then transferred in a dedicated micro-
tube and then stored at −20°C or, preferably, −80°C.
Randomization
Allocation of study treatment was performed via a
Web-based interactive randomization system available at
https://trials.advicepharma.com/hitech. Randomization
was achieved with computer-generated random sequence
with a random block size (from X to Y) stratified according
to the clinical site and the presence of diabetes mellitus.
Treatment protocol and follow-up
All patients received DAPT for the entire duration of the
study, which included aspirin (75-160 mg/d orally) and, in
random order, clopidogrel (600 mg orally as LD followed
by 75 mg/d) for 30 ± 5 days, prasugrel (60 mg orally as LD
followed by 10 mg/d, or 5 mg/d if age ≥75 years and/or
weight ≤60 kg) for 30 ± 5 days, and ticagrelor (180 mg
orally as LD followed by 90 mg twice a day) for 30 ± 5
days. Follow-up visit schedule is shown in Figure 1.
Study end points
The primary objective of the study is RHI at treatment
steady state (ie, after 30 ± 5 days of treatment), evaluated
with EndoPAT system and assessed 1-2 hours after intake
Published in final edited form as: Am Heart J. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.017of the daily (for clopidogrel or prasugrel) or morning (for 
ticagrelor) maintenance dose of each investigated P2Y12
inhibitor. The primary end point consists of 2 main 
comparisons: ticagrelor vs prasugrel difference in RHI, 
and ticagrelor vs clopidogrel difference in RHI.
The secondary objectives include RHI 1-2 hours after 
P2Y12 inhibitor LD or prior MD administration and other 
biomarkers of endothelial function. Each of these 
secondary end points encompasses 2 main comparisons: 
ticagrelor vs prasugrel difference, and ticagrelor vs 
clopidogrel difference. The comparison between 
prasugrel and clopidogrel in terms of RHI and circulating 
biomarkers will be also reported for exploratory 
purposes.
Statistical considerations
The null hypothesis (H0) of this study is that the 
primary end point (difference in RHI at treatment steady 
state) does not differ during ticagrelor treatment as 
compared with prasugrel or clopidogrel. The alternative 
hypothesis (H1) is that the primary end point differs after 
ticagrelor as compared with prasugrel or clopidogrel. 
Sample size calculation was based on repeated 2-way 
analysis of variance (ANOVA),20 setting mean RHI at 1.8 
with a within-subjects SD of 0.31. Hence, 36 patients 
completing all sequences (ie, 6 patients/sequence) 
provides 90% power to detect a 10% RHI relative change 
in ticagrelor group with a 2-sided α level at 5%. To 
account for dropouts as well as incomplete data 
assessments, the final sample size was increased up to 
≥50 patients.
The primary end point will be analyzed using repea-ted-
measures on1-factorial ANOVA (ANOVA with 3 levels as 
treatment factor to account for each of the 3 tested P2Y12 
inhibitor). Correction for possible intragroup correlation 
will be done by the Greenhouse-Geisser method. The 
ANOVA will yield the differences between the 2 main 
comparisons, ticagrelor RHI vs prasugrel RHI and 
ticagrelor RHI vs clopidogrel RHI. To assess the primary 
end point, the significance of these 2 main comparisons 
will be combined using the Hochberg-Benjamini 
method41 as follows: the H0 of randomized treatment 
equivalence comparing the response in RHI after 
ticagrelor vs prasugrel administration and the response in 
RHI after ticagrelor vs clopidogrel administration is rejected if 
significance is achieved for both main comparisons at a 2-
sided α level of .05 (ie, the difference in RHI ticagrelor vs 
prasugrel is supported with P value b .05 and the difference 
in RHI ticagrelor vs clopidogrel is supported with P value 
b .05), or for one comparison at a 2-sided α level of .025 (ie, 
the difference in RHI ticagrelor vs prasugrel is supported 
with P value b .025 or the difference in RHI ticagrelor vs 
clopidogrel is supported with P value b .025).
Each of the secondary end points will be analyzed using 
the same predefined statistical assumptions, combining 
the P values of the 2 main comparisons. The H0 will be 
rejected if either comparison yields a P value b .025 orwhen both comparisons yield P values b .05. See
Supplementary appendix for further explanation and
for examples regarding the application of the Benjamini-
Hochberg in our experimental setting (Supplementary
Table VI).
The third comparison (ie, the difference in response
between prasugrel and clopidogrel) will be reported as
explorative unpowered end point.
The SWAP-2 study showed that switching over to
prasugrel from previous treatment with ticagrelor results
in a progressive decline in PLT inhibition (leading to a
clear rebound effect if no LD is given) as compared with
the continuation of treatment with ticagrelor. Hence, it
may be assumed that any measurement performed during
the early phase of any switch from one to another P2Y12
inhibitor may be confounded (ie, it may also at least
partially reflect prior exposure to the earlier P2Y12
inhibitor). Based on the timing of blood sampling in this
study, one may assume this carryover effect to disappear
from after 48 hours and up to 7 days. This was the rational
for setting the primary EP measure remotely, that is, at 30
days after each crossover. Nevertheless, methodologies
that account for any possible carryover effect, such as
analysis of covariance and stratified analysis based on the
randomized sequence as well as nonrandomized type of
P2Y12 inhibitor before randomization, will be applied for
multiple sensitivity analyses for all primary and secondary end
points. It is also prespecified that for these sensitivity analyses,
clopidogrel andprasugrelwill be handled separately aswell as
lumped together in the thienopyridines group.
Stratified analysis of the primary end point will be also
carried out according to sex, age, presence of diabetes,
hypertension, active smoking, dyslipidemia, body mass
index, study site, number of vessels diseased, type of ACS
at presentation, randomization sequence, and prerando-
mization P2Y12 inhibitor intake.
Predefined subanalyses and substudies
Prespecified subanalyses and substudies include, but
are not limited to, the evaluation of adenosine plasma
concentration, adherence to study drugs, and effect of
age or concomitant drugs on primary or secondary end
point measures of endothelial function and FMD results.
Study organization
The HI-TECH study was conducted at 5 investigative sites
in 4 European countries, including Switzerland, Italy, Spain,
and the Netherlands. The final study protocol and informed
consent have been reviewed and approved by the ethics
boards/institutional reviewboards and corresponding health
authorities for all participant study sites/countries. The study
is an investigator-driven clinical trial partially supportedby an
unrestricted research grant from AstraZeneca. The authors
are solely responsible for the design and conduct of this
study; all study analyses; and drafting and editing of the
manuscript. Data are being coordinated and analyzed by an
. 
t 
 
 
Published in final edited form as: Am Heart J. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.017academic Clinical Trial Unit located in Bern, Switzerland
The trial registration number is NCT02587260 available a
https://register.clinicaltrials.gov/prs/app/action/
LoginUser?uid=U0002SC5&ts=167&cx=-f91kzu. Indepen-
dent study monitoring was performed by AdvicePharma
(Milan, Italy). The Electronic Data Capture was designed by
the investigators and Web-implemented by AdvicePharma. 
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l Conclusions
The HI-TECH study is the first randomized, crossover study
aiming to ascertain whether ticagrelor, when administered a
approved regimen in post-ACS patients, improves endothelia
function as compared with both clopidogrel and prasugrel
The first patient was randomized on December 2015 and the
last on October 2016 with a total of 54 patients. The las
follow-up visit was performed on February 2017 and the fina
results are expected in the third quarter of 2017.-
l 
 
, 
 
 
 
 
 
 
, 
 
Disclosures
Salvatore Brugaletta received lectures fees from AstraZe
neca, Abbott, and Boston, and has received institutiona
research grant from AstraZeneca. Sergio Leonardi received
personal fees from AstraZeneca, The Medicine Company
Merck, Daiichi Sankyo, and Ely Lilly, and institutional research
grants from AstraZeneca and Daiichi Sankyo. K. Stephan
Windecker received research contracts to the institution from
Abbott, Biotronik, Boston Scientific, Medtronic, Edwards
Lifesciences, and St Jude. Marco Valgimigli has received
speaker's fees from AstraZeneca, Biosensor, and Terumo, and
has received institutional research grants from AstraZeneca
The Medicines Company, and Terumo. Other authors have
nothing to declare.M.V. designed the study and obtained funding. M.V.
and S.A. contributed to protocol development. M.V. and 
S.A. actively participated in the writing of the manuscript. 
D.H. contributed to the statistical analysis and actively
participated in the writing of the statistical sections of the
manuscript. All authors critically reviewed the manu-
script and approved the final version.
ContributorshipReferences
1. Torngren K, Ohman J, Salmi H, et al. Ticagrelor improves peripheral
arterial function in patients with a previous acute coronary syndrome.
Cardiology 2013;124:252-258.2. Fromonot J, Dignat-Georges F, Rossi P, et al. Ticagrelor improves peripheral
arterial function in acute coronary syndrome patients: relationship with
adenosine plasma level. J Am Coll Cardiol 2016;67:1967-1968.
3. Xanthopoulou I, Vogiatzi C, Bampouri T, et al. Lack of evidence for
deterioration in endothelial function following ticagrelor treatment
cessation. Curr Vasc Pharmacol 2016;14:487-491.
4. Flammer AJ, Luscher TF. Human endothelial dysfunction: EDRFs.
Pflugers Arch 2010;459:1005-1013.
5. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction:
EDCFs. Pflugers Arch 2010;459:1015-1023.
6. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of
endothelial function: from research into clinical practice. Circulation
2012;126:753-767.
7. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary
vascular endothelial dysfunction. Circulation 2002;106:653-658.
8. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification
of patients with early coronary atherosclerosis by assessment of digital
reactive hyperemia. J Am Coll Cardiol 2004;44:2137-2141.
9. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular
endothelial function with finger arterial pulse wave amplitude. Am
Heart J 2003;146:168-174.
10. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial
function by non-invasive peripheral arterial tonometry predicts late
cardiovascular adverse events. Eur Heart J 2010;31:1142-1148.
11. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of
ticagrelor: evidence and potential clinical relevance. J Am Coll
Cardiol 2014;63:2503-2509.
12. Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine
plasma concentration in patients with an acute coronary syndrome. J
Am Coll Cardiol 2014;63:872-877.
13. Ohman J, Kudira R, Albinsson S, et al. Ticagrelor induces adenosine
triphosphate release from human red blood cells. Biochem Biophys
Res Commun 2012;418:754-758.
14. Grzesk G, Kozinski M, Navarese EP, et al. Ticagrelor, but not
clopidogrel and prasugrel, prevents ADP-induced vascular smooth
muscle cell contraction: a placebo-controlled study in rats. Thromb Res
2012;130:65-69.
15. Armstrong D, Summers C, Ewart L, et al. Characterization of the
adenosine pharmacology of ticagrelor reveals therapeutically rele-
vant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc
Pharmacol Ther 2014;19:209-219.
16. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions
for cardiovascular clinical trials: a consensus report from the Bleeding
Academic Research Consortium. Circulation 2011;123:2736-2747.
17. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations
of digital vascular function to cardiovascular risk factors in the
Framingham Heart Study. Circulation 2008;117:2467-2474.
18. Sauder KA, West SG, McCrea CE, et al. Test-retest reliability of
peripheral arterial tonometry in the metabolic syndrome. Diab Vasc
Dis Res 2014;11:201-207.
19. Liu J, Wang J, Jin Y, et al. Variability of peripheral arterial tonometry
in the measurement of endothelial function in healthy men. Clin
Cardiol 2009;32:700-704.
20. McCrea CE, Skulas-Ray AC, Chow M, et al. Test-retest reliability of
pulse amplitude tonometry measures of vascular endothelial function:
implications for clinical trial design. Vasc Med 2012;17:29-36.
21. Selamet Tierney ES, Newburger JW, Gauvreau K, et al. Endothelial
pulse amplitude testing: feasibility and reproducibility in adolescents.
J Pediatr 2009;154:901-905.
22. Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and
impaired endothelial function in healthy adolescent women. J Behav
Med 2008;31:137-143.
Published in final edited form as: Am Heart J. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.01723. Black MA, Cable NT, Thijssen DH, et al. Importance of measuring the
time course of flow-mediated dilatation in humans. Hypertension
2008;51:203-210.
24. Harris RA, Padilla J, Hanlon KP, et al. Reproducibility of the
flow-mediated dilation response to acute exercise in overweight men.
Ultrasound Med Biol 2007;33:1579-1585.
25. Jarvisalo MJ, Jartti L, Marniemi J, et al. Determinants of short-term
variation in arterial flow-mediated dilatation in healthy young men.
Clin Sci (Lond) 2006;110:475-482.
26. Donald AE, Halcox JP, Charakida M, et al. Methodological
approaches to optimize reproducibility and power in clinical studies
of flow-mediated dilation. J Am Coll Cardiol 2008;51:1959-1964.
27. Ghiadoni L, Faita F, Salvetti M, et al. Assessment of flow-mediated
dilation reproducibility: a nationwide multicenter study. J Hypertens
2012;30:1399-1405.
28. Bailey DM, Rimoldi SF, Rexhaj E, et al. Oxidative-nitrosative stress
and systemic vascular function in highlanders with and without
exaggerated hypoxemia. Chest 2013;143:444-451.
29. Jayet PY, Rimoldi SF, Stuber T, et al. Pulmonary and systemic vascular
dysfunction in young offspring of mothers with preeclampsia.
Circulation 2010;122:488-494.
30. Rimoldi SF, Rexhaj E, Pratali L, et al. Systemic vascular dysfunction in
patients with chronic mountain sickness. Chest 2012;141:139-146.
31. Rimoldi SF, Sartori C, Rexhaj E, et al. Antioxidants improve vascular
function in children conceived by assisted reproductive technologies:
a randomized double-blind placebo-controlled trial. Eur J Prev
Cardiol 2015;22:1399-1407.
32. Iglarz M, Clozel M. Mechanisms of ET-1–induced endothelial
dysfunction. J Cardiovasc Pharmacol 2007;50:621-628.33. Sibal L, Agarwal SC, Home PD, et al. The role of asymmetric
dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular
disease. Curr Cardiol Rev 2010;6:82-90.
34. Lu TM, Ding YA, Lin SJ, et al. Plasma levels of asymmetrical
dimethylarginine and adverse cardiovascular events after percutaneous
coronary intervention. Eur Heart J 2003;24:1912-1919.
35. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events
and serum concentration of asymmetrical dimethylarginine. Lancet
2001;358:2127-2128.
36. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical
dimethylarginine independently predicts total and cardiovascular
mortality in individuals with angiographic coronary artery disease (the
Ludwigshafen Risk and Cardiovascular Health study). Clin Chem
2007;53:273-283.
37. Lip GY, Blann A. von Willebrand factor: a marker of endothelial
dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-265.
38. Zhukov O, Popov J, Ramos R, et al. Measurement of von Willebrand
factor–FVIII binding activity in patients with suspected vonWillebrand
disease type 2N: application of an ELISA-based assay in a reference
laboratory. Haemophilia 2009;15:788-796.
39. Castaman G, Tosetto A, Cappelletti A, et al. Validation of a rapid test
(VWF-LIA) for the quantitative determination of von Willebrand factor
antigen in type 1 vonWillebrand disease diagnosis within the European
multicenter study MCMDM-1VWD. Thromb Res 2010;126:227-231.
40. Vinholt PJ, Overgaard M, Diederichsen AC, et al. An ELISA for the
quantitation of von Willebrand factor: osteoprotegerin complexes in
plasma. Thromb Res 2013;131:396-400.
41. Hochberg Y, Benjamini Y. More powerful procedures for multiple
significance testing. Stat Med 1990;9:811-818.
